Corvas shifts opportunistically

Corvas International Inc., long thought of as a cardiovascular company with a small inflammatory program, has been shifting the weight of its research and is now devoting about 40 percent of its resources to the latter. The change is a result of the discovery last year of neutrophil inhibitory factor (NIF), a protein that acts as an antagonist to the